Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI ... MarketWatch (press release) Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study. Dr. Susan M. O'Brien et al. |
